teroxirone has been researched along with Neoplasms* in 5 studies
5 other study(ies) available for teroxirone and Neoplasms
Article | Year |
---|---|
Phase I study of two schedules of teroxirone.
Two schedules of teroxirone, a triazine triepoxide, were evaluated in a phase I study. Twenty-six patients were treated on 1 day every 5 weeks at doses of 36-2250 mg/m2. At doses greater than or equal to 1500 mg/m2, severe thrombophlebitis was seen without cytotoxic effect, and this schedule was closed. Twenty-seven patients were treated on 5 days every 5 weeks at daily doses of 16-450 mg/m2. Mild thrombophlebitis and moderate leukopenia were encountered. For phase II studies, a dose of 375 mg/m2 X 5 every 5 weeks is recommended. Pharmacologic studies showed rapid plasma elimination, which suggests the agent's possible usefulness for regional infusion. Topics: Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Humans; Leukopenia; Neoplasms; Thrombophlebitis; Triazines | 1987 |
Phase I trial of teroxirone.
Teroxirone is a novel triepoxide, synthesized as an alkylator and showing a broad spectrum of preclinical activity. It has good cytotoxic activity against sublines of P388 and L1210 leukemias resistant to another alkylating agent, cyclophosphamide. Thirty-six patients received teroxirone as a single iv push for 5 sequential days every 4 weeks. The dose-limiting toxic effects were phlebitis and cutaneous "flare" reactions, with a maximal tolerated dose of 340 mg/m2/day X 5. Nausea, vomiting, and myelosuppression were present but were not dose-limiting at the maximal tolerated dose. This dose would probably be a reasonable dose for phase II trials, but could not be delivered repeatedly without a central line. Since the local reactions were very severe and unique, we believe that studies on the safety of repeated administration via a central line should be completed in animals before trials of systemic therapy in humans begin. Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Neoplasms; Thrombophlebitis; Triazines | 1984 |
Preclinical evaluation of the anti tumour activity of new epoxyde derivatives.
As a follow-up to our initial results on the antineoplastic activity of alpha-1,3,5-triglycidyl-s-triazinetrione (alpha TGT, NSC-296934, Teroxirone), many new epoxyde derivatives were tested against murine tumours, mostly against P388 leukaemia, to determine their antineoplastic role and to characterize their specific effect against tumour cells in vivo, as well as to select an analogue with higher anti-cancer properties and superior pharmacological properties. Triglycidyl urazol (TGU, NSC-332488) showed the highest therapeutic activity and a good level of water-solubility which makes this agent a good candidate for phase-one clinical trials. Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Evaluation, Preclinical; Epoxy Compounds; Ethers, Cyclic; Female; Leukemia L1210; Leukemia P388; Mice; Mice, Inbred Strains; Neoplasms; Triazines | 1984 |
Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934).
alpha-1,3,5-Triglycidyl-s-triazinetrione (TGT) is a triepoxide derivative with alkylating properties discovered by random screening. TGT has been found to be active against a wide variety of murine tumors, including a P388 subline resistant to cyclophosphamide. The starting dose in this phase-I study was 30 mg/m2 as a single dose IV, repeated every 3-4 weeks, increasing up to 2,700 mg/m2. Severe dose-limiting toxicity took the form of phlebitis becoming apparent a few days after treatment. This was initially seen at the 480 mg/m2 dose level, and was observed with increasing frequency and intensity at higher dose levels. Leukopenia occurred regularly at dose levels above 1,800 mg/m2 and resulted in life-threatening leukopenia in one patient, and in a toxic death at 2,700 mg/m2 in another patient. Other toxic side-effects included moderate reversible thrombocytopenia, nausea, and vomiting. It is recommended that further trials with TGT await the development of more water-soluble formulations or of other triepoxide derivatives. Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Triazines; Vomiting | 1983 |
Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934).
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Infusions, Parenteral; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Thrombophlebitis; Triazines; Vomiting | 1981 |